Senior woman header
Senior woman header
Photo header of senior man
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test™ to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.

Learn More
Senior woman header
Senior woman header
Senior man header
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test™ to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.
Learn More

Introducing the Syn-One Test™ from CND Life Sciences

Offering physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy.

seal icon

CLIA-Certified Pathology Lab

test tube icon

Dedication to Science & Research

DNA icon

Patient-Focused Mission

microscope icon

Quality & Reliability at Our Core

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
February 24, 2021

CND Life Sciences Supports Rare Disease Day

Rare Disease Day is February 28, 2021. EURORDIS, the organizer of Rare Disease Day, works…
Insights
January 29, 2021

CND Life Sciences Launches Patient Matters Video Series to Highlight the Importance of the Syn-One Test™ in Diagnosing Neurological Disorders

A core value of CND Life Sciences is putting patients first. We understand that there’s…
Insights
January 19, 2021

We Can Perform Early Screening for Neurodegenerative Disorders. Does That Mean We Should?

In the November 2020 issue of Movement Disorders, Dommershuijsen and his fellow researchers in the…
VIEW ALL INSIGHTS

Check out press releases, news alerts and coverage of CND happenings.

In the News
February 16, 2021

Alterity Therapeutics Receives Grant to Study ATH434 in Parkinson’s Disease

Alterity Therapeutics announced that it has received a second grant from The Michael J. Fox…
In the News
February 4, 2021

Researchers Identify Proteins With Potential to Treat Parkinson’s Disease

Parkinson’s is a complicated neurological disorder that researchers are continuously working to understand. However, a…
News Release
January 7, 2021

CND Life Sciences to Present at Biotech Showcase Investor Conference

Poised for Growth After Successfully Launching First Skin-Based Test for Parkinson's
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Syn-One Test™ Kit

The Syn-One Test provides objective pathological evidence to aid in the diagnosis of a synucleinopathy. Simply collect three small punch skin biopsies from your patient, send them to our CLIA-certified lab, and CND Life Sciences will provide important visual insights to support a diagnosis. If you are a clinician, click below to order a Syn-One Test Biopsy Kit.

Order a Kit